MEN 2 (multiple endocrine neoplasia type 2) is an inherited syndrome that predisposes people to developing medullary thyroid carcinoma, a rare thyroid cancer.
Because of that link, a personal or family history of MEN 2 is listed as a contraindication on GLP-1 medication labeling.